(ISEE)

業務介紹

艾維瑞克生物公司(IVERIC bio, Inc.)是一家生物製藥公司,專注於發現和開發治療視網膜疾病的創新療法,尤其是與年齡相關的和罕見遺傳性視網膜疾病(IRDs)。

該公司開發了Zimura,這是一種補體因子C5抑制劑,包括已完成2/3期臨床試驗的GATHER1,以及正在進行3期臨床試驗的GATHER2,用於治療乾性老年性黃斑變性(GA)引起的地理性萎縮。

該公司還開發了STAR或OPH2005,正在進行2b期臨床試驗,用於治療先天性阿馬羅斯10型(LCA10)和常染色體隱性斯塔格特病(STGD1)。此外,還有IC-500(用於治療GA和其他與年齡相關的視網膜疾病的高溫要求A絲氨酸肽酶1蛋白抑制劑)、IC-100(用於治療視紅素介導的常染色體顯性retinitis pigmentosa)和IC-200(用於治療與BEST1基因突變相關的IRDs)。

該公司還開發了OPH2001(Zimura單藥治療GA的1/2a期臨床試驗已完成)、OPH2000(Zimura聯合Lucentis治療濕性AMD的1/2a期臨床試驗已完成)、OPH2007(濕性AMD的2a期臨床試驗已完成)和OPH2002(特發性脈絡膜血管病變的2a期臨床試驗已完成)。

此外,該公司的發現和研究項目包括miniCEP290項目(用於LCA10)、miniABCA4項目(用於STGD1)和miniUSH2A項目(用於2A型視網膜色素變性相關的IRDs)。

該公司原名為Ophthotech Corporation,於2019年4月更名為IVERIC bio, Inc.,成立於2007年,總部位於新澤西州帕西帕尼。



IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

公司網址

https://ivericbio.com